Move Over Gilead? AbbVie Could Bring Serious Competition to HCV Market
13. Oktober 2014 12:25 ET
|
Real Endpoints
WESTPORT, CT--(Marketwired - Oct 13, 2014) - Gilead's Harvoni (sofosbuvir/ledipasvir combination) is the top overall scorer, according to RxScorecard, a drug-value assessment tool from Real...
Cancer Drug Costs Unsustainable, According to Value & Innovation Webinar
30. März 2012 11:32 ET
|
Value & Innovation
WESTPORT, CT--(Marketwire - Mar 30, 2012) - The current economic model for treating cancer is badly broken, according to senior executives from healthcare insurance companies who discussed the...